Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2021-10-21 Earnings Release
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Third quarter 2021 financial report
Earnings Release Classification · 100% confidence The document is explicitly titled "Third quarter 2021 financial report" and immediately announces the results for Q3 2021, providing key financial highlights (revenue, EBITDA) and operational updates for that period. This content structure—a summary of results for a specific interim period (Q3)—is characteristic of an Interim/Quarterly Report (IR). Although it mentions a webcast, the core content is the financial summary, not just the announcement of the report's release (which would be RPA/RNS). It is not the full Annual Report (10-K) as it covers only Q3. Q3 2021
2021-10-21 English
Flaggemelding
Director's Dealing Classification · 95% confidence The document is titled "Flaggemelding" (Flagging Announcement in Norwegian) and details a transaction where a group of related companies acquired 85,000 shares, resulting in their total ownership crossing the 10% threshold in Gentian Diagnostics ASA. This type of announcement, reporting changes in significant share ownership by insiders or related parties, directly corresponds to the definition of Major Shareholding Notification (MRQ) or potentially Director's Dealing (DIRS) if the entities were directors, but given the focus on crossing a significant ownership threshold (10%), MRQ is the most precise fit among the provided options, although DIRS is also plausible for insider transactions. Since the text explicitly states the group's ownership is now over 10% after the transaction, it is a notification of a major shareholding change. Given the options, MRQ (Major Shareholding Notification) is the best fit for reporting ownership crossing a significant threshold.
2021-10-11 Norwegian
Product and market developments update
Regulatory Filings Classification · 95% confidence The document is dated October 5, 2021, and provides an update on product milestones (GCAL, SARS-CoV-2 Ab, NT-proBNP) and project timelines, including a delay in the NT-proBNP launch. It also announces an upcoming R&D presentation in connection with the Q3 results release on October 21. This content is characteristic of an update on operational progress and pipeline development, rather than a formal financial report (like 10-K or IR) or a simple announcement of a report's publication (RPA). Since it details specific business developments, project statuses, and pipeline progress, it fits best under Investor Presentation (IP) or potentially Regulatory Filings (RNS) if it were a mandatory disclosure. Given the detailed, forward-looking operational update, 'Investor Presentation' (IP) is the most appropriate classification, as these updates often form the basis of investor presentations, even if this specific text is a press release format. It is not a formal financial statement, earnings release (ER), or a management discussion (MDA) which usually accompanies formal results. It is a specific update on R&D and commercial progress.
2021-10-05 English
Product and market developments update
Regulatory Filings Classification · 100% confidence The document is titled "Product and market developments update" and provides specific updates on project milestones (GCAL, SARS-CoV-2 Ab, NT-proBNP), commercial negotiations, and pipeline progress. It concludes with an invitation to an R&D presentation in connection with the Q3 results release on October 21st. This content is characteristic of an update provided to investors regarding operational progress and near-term outlook, often released outside of the formal quarterly earnings release (ER) or annual report (10-K). Since it details operational and product development progress rather than just announcing results or a formal meeting, it aligns best with an Investor Presentation (IP) or a general update that serves a similar purpose. Given the detailed nature of the R&D updates and the context of an upcoming Q3 results presentation, 'Investor Presentation' (IP) is the most fitting category, as it functions as an investor communication detailing strategy and progress.
2021-10-05 English
Invitation to presentation of third quarter results
Report Publication Announcement Classification · 98% confidence The document is titled 'Invitation to presentation of third quarter results' and explicitly invites participants to a webcast presentation of the 2021 third quarter results scheduled for October 21st. This is not the full earnings release (ER) or the interim report (IR) itself, but rather an announcement about the upcoming presentation of those results. According to Rule 2, if a document is short and announces the publication or presentation of results/reports, it should be classified as a Report Publication Announcement (RPA).
2021-10-05 English
Norron Sicav Flagging i Gentian Diagnostics ASA
Major Shareholding Notification Classification · 98% confidence The document text is very short (529 characters) and announces a change in share ownership by Norron Sicav in Gentian Diagnostics ASA. Specifically, it states that Norron sold shares causing their holding to cross below the 5% threshold. This type of notification regarding changes in significant share ownership levels directly corresponds to the definition of Major Shareholding Notification (MRQ). It is not a full report, an earnings release, or a director's dealing (as it concerns a fund manager/entity, not an individual director).
2021-09-08 Norwegian

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.